Spyre Therapeutics
SYRE
SYRE
43 hedge funds and large institutions have $31.9M invested in Spyre Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
2% less funds holding
Funds holding: 44 → 43 (-1)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Holders
43
Holding in Top 10
2
Calls
–
Puts
$1K
Top Buyers
| 1 | +$4.26M | |
| 2 | +$3.97M | |
| 3 | +$2.86M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.25M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$2.21M |
Top Sellers
| 1 | -$1.55M | |
| 2 | -$871K | |
| 3 | -$608K | |
| 4 |
Millennium Management
New York
|
-$578K |
| 5 |
O
OrbiMed
New York
|
-$521K |